Classifying Cancers Based on T-cell Infiltration and PD-L1.
about
Checkpoint Inhibitors and Their Application in Breast CancerUveal melanoma as a target for immune-therapyEngineering opportunities in cancer immunotherapyAdaptive Immune Resistance: How Cancer Protects from Immune AttackHigh-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint TracersPD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancerIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsFocus on Nivolumab in NSCLCValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationThe role of immune checkpoint inhibition in the treatment of ovarian cancerBeyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma.PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.Anti-CD73 in cancer immunotherapy: awakening new opportunities.Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyA humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancerTargeting CD73 in the tumor microenvironment with MEDI9447.Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer.Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancersThe prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapyIntratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.What does PD-L1 positive or negative mean?The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.
P2860
Q26745442-95A755A3-DD57-4374-B87E-CA0C8DD3FEF6Q26747519-838BDA2D-42C1-46B2-806B-C6A7539EFDBEQ26776373-1F76A704-9E4F-459C-8B93-8C08826C6EC9Q26798448-F1E184E0-A62B-4EA5-87DD-0713FD38A909Q27300777-48359F03-23B0-45EE-91ED-4E8E463A5E96Q27853353-334D55B3-8C4D-4227-BBA3-B2C9B261223DQ28072263-3A8D49F4-30FE-477C-9EBD-D9ABD262B237Q28072532-F9CD336C-3BDC-4EC3-96E3-16A213C0FA10Q28073759-ED053962-EB8B-42E5-A288-FCCFD525F4E8Q28075719-B2D31EBA-02AA-4587-924B-6BD541FBD360Q28077924-C5AEEC01-688E-4327-BD89-7F94E4C20F03Q30276874-65517286-58AA-4DBE-9E3F-FFEB867544FFQ31137039-81948D7B-AB68-4EF5-827C-78CCC4A6062BQ33586463-18628F9B-87FF-4E7F-B0B7-040BF99F6E8BQ33688662-A3639255-553E-4B47-8F55-5492261660ADQ33688849-1410618F-195F-4A9C-ACAD-384E29A0ABA8Q33728267-44C34ACC-582E-4C59-8623-47EE0D2C1B1BQ33728298-D2D4174A-F23D-447A-81BE-F66153A68564Q33802505-36BBAFE6-CA69-4BCA-A423-92A0E3656DAAQ33839204-059C09E5-41A0-40F7-AD37-63D65E2CE25CQ33915040-D0718136-FDA5-4CFC-9324-5F1EFAA8CC20Q36709157-5542C669-F12A-44DA-9DF8-8265F124B6B6Q36821239-2E38026B-E13E-4663-B4E2-E9AA1BD01C2DQ36898404-6B6BAFF1-4E96-468C-859B-202859A4CCA8Q36962925-E71516A6-0222-40F7-9F72-6B39C3EB81C9Q37113485-AAC8F266-FA07-4634-9930-B371185D3633Q37224639-9DFC0E08-7D39-4262-ACA1-0C80DD216518Q37281262-011CC189-867E-4F9E-AFED-F3ED74C8652AQ37335249-1C6672CD-5C91-4F4B-9BB6-ED32784212C5Q37362803-658A704C-8B52-48D3-996F-930876994D3DQ37376414-4324C0A5-4476-401F-9DCA-292E5315EF22Q37469720-F39E3E9C-BD75-4C67-B998-5F433102D5D4Q37500381-70821DCF-5636-4519-B1C0-903C790A5DE6Q37516448-7D139F2B-8BF2-4BEF-A6AD-62976CD98056Q37520133-F9825EA9-1DC5-4F2B-B679-8B90BEC4A3BCQ37616487-12CF10EA-618E-4534-8C10-9FF2FB2FE234Q37687636-84EAC82C-E740-4327-A0CD-75866E3E9874Q37705021-C00ACE0A-E4E7-41BA-AA8B-53D837F4EA70Q37716582-14FBD9FD-54AD-4EF6-8E7C-8349FB27CD9BQ37718304-74AA302D-9B2C-4571-8761-A2DE743F38F5
P2860
Classifying Cancers Based on T-cell Infiltration and PD-L1.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Classifying Cancers Based on T-cell Infiltration and PD-L1.
@ast
Classifying Cancers Based on T-cell Infiltration and PD-L1.
@en
type
label
Classifying Cancers Based on T-cell Infiltration and PD-L1.
@ast
Classifying Cancers Based on T-cell Infiltration and PD-L1.
@en
prefLabel
Classifying Cancers Based on T-cell Infiltration and PD-L1.
@ast
Classifying Cancers Based on T-cell Infiltration and PD-L1.
@en
P2093
P2860
P1433
P1476
Classifying Cancers Based on T-cell Infiltration and PD-L1.
@en
P2093
Antoni Ribas
Michele W L Teng
Shin Foong Ngiow
P2860
P304
P356
10.1158/0008-5472.CAN-15-0255
P407
P577
2015-06-01T00:00:00Z